Lexicon Pharmaceuticals, Inc. (LXRX)

NCM – Цена в реальном времени. Валюта: USD

2.41

+0.10 (4.33%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.45

+0.04 (1.66%)

До открытия: May 13, 2026, 5:37 AM EDT

12.05.2026

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.

08.05.2026

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.

07.05.2026

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

07.05.2026

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

07.05.2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. “We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said Mike Exton, Ph.D.

04.05.2026

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.

30.04.2026

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

04.05.2026

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

24.03.2026

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action

23.03.2026

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon Pharmaceuticals, Inc. (LXRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Видео

No Data

Пресс-релизы

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Видео

No Data

Пресс-релизы

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Search stocks

Lexicon Pharmaceuticals, Inc. (LXRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Видео

No Data

Пресс-релизы

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Видео

No Data

Пресс-релизы

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851